• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Burns - Pipeline Review, H2 2012 Product Image

Burns - Pipeline Review, H2 2012

  • ID: 2298688
  • October 2012
  • 88 pages
  • Global Markets Direct

Burns – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Burns - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Burns, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burns. Burns - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Burns.
- A review of the Burns products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Burns Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Burns 10
Burns Therapeutics under Development by Companies 12
Burns Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Burns Therapeutics – Products under Development by Companies 21
Burns Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Burns Therapeutics Development 23
MediWound Ltd. 23
CytoTools AG 24
Shenzhen Beike Biotechnology Co., Ltd. 25
Healthpoint, Ltd. 26
TetraLogic Pharmaceuticals 27
Glycotex, Inc. 28
NanoBio Corporation 29
Adocia 30
Fibrocell Sciences, Inc. 31
Se-cure Pharmaceuticals Ltd. 32
AlgiPharma AS 33
Birken GmbH 34
Burns – Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 42
Mebo - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ICX-SKN - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
GLYC-101 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Neu-2000 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Necrostatin Program - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
azficel-T - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Peptid - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
opebacan - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
amnion - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
caspofungin acetate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Biochaperone PDGF-BB - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Debrase Gel Dressing - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
becaplermin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Cultured Autologous Keratinocytes - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
interferon alfa-2b - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
KUR-212 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
NB-201 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Levamizole - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Oleogel-S-10 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
propranolol hydrochloride - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
HO/03/06 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Human Umbilical Cord Mesenchymal Stem Cells - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Human Cord Blood Mononuclear Cells + Human Umbilical Cord Mesenchymal Stem Cells - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
N2 Peptide - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SC-106 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Burns Therapeutics – Drug Profile Updates 75
Burns Therapeutics – Discontinued Products 80
Burns Therapeutics - Dormant Products 81
Burns – Product Development Milestones 82
Featured News & Press Releases 82
Jan 09, 2012: NovaBay Pharmaceuticals Announces Strategic Marketing Agreement For NeutroPhase In China 82
Apr 04, 2011: Cubist Pharma Settles CUBICIN Patent Litigation With Teva 83
Dec 08, 2010: DPT Receives FDA Approval To Commercially Manufacture Collagenase SANTYL Sterile Ointment 83
Oct 12, 2010: Nanobio And The University Of Michigan Awarded $1.5M Department Of Defense Grant To Study Topical Anti-Infective Treatment For Combat Related Injuries 84
Sep 14, 2009: NanoBio Presents Key Data On The Use Of Nanoemulsions To Treat Burn Wound Infections 85
Aug 12, 2009: Kuros Announces Encouraging Phase IIa Data With KUR-212 In Patients With Burns Requiring Mesh Grafting 85
Aug 11, 2008: Kuros Announces Results Of One-Month Follow-Up Of Phase IIa Trial Of KUR-212 In Patients With Burns Requiring Mesh Grafting 86
Feb 04, 2008: Kuros Completes Patient Recruitment In Phase Lia Trial Of KUR 212 In Patients With Severe Burns Requiring Meshed Skin Grafting 86
Jan 16, 2008: Glycotex, Inc. Receives $0.5 Million From Second Tranche Of Private Share Placement 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 88
Disclaimer 88

List of Tables
Number of Products Under Development for Burns, H2 2012 10
Products under Development for Burns – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Development by Companies, H2 2012 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2012 16
Comparative Analysis by Late Stage Development, H2 2012 17
Comparative Analysis by Mid Clinical Stage Development, H2 2012 18
Comparative Analysis by Early Clinical Stage Development, H2 2012 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 22
MediWound Ltd., H2 2012 23
CytoTools AG, H2 2012 24
Shenzhen Beike Biotechnology Co., Ltd., H2 2012 25
Healthpoint, Ltd., H2 2012 26
TetraLogic Pharmaceuticals, H2 2012 27
Glycotex, Inc., H2 2012 28
NanoBio Corporation, H2 2012 29
Adocia, H2 2012 30
Fibrocell Sciences, Inc., H2 2012 31
Se-cure Pharmaceuticals Ltd., H2 2012 32
AlgiPharma AS, H2 2012 33
Birken GmbH, H2 2012 34
Assessment by Monotherapy Products, H2 2012 35
Assessment by Combination Products, H2 2012 36
Assessment by Stage and Route of Administration, H2 2012 38
Assessment by Stage and Molecule Type, H2 2012 41
Burns Therapeutics – Drug Profile Updates 75
Burns Therapeutics – Discontinued Products 80
Burns Therapeutics – Dormant Products 81

List of Figures
Number of Products under Development for Burns, H2 2012 10
Products under Development for Burns – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 15
Late Stage Products, H2 2012 17
Mid Clinical Stage Products, H2 2012 18
Early Clinical Stage Products, H2 2012 19
Discovery and Pre-Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 35
Assessment by Combination Products, H2 2012 36
Assessment by Route of Administration, H2 2012 37
Assessment by Stage and Route of Administration, H2 2012 38
Assessment by Molecule Type, H2 2012 39
Assessment by Stage and Molecule Type, H2 2012 40

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos